financetom
Business
financetom
/
Business
/
Stratasys Surges on Revenue Beat, Eyes Growth Amid Additive Manufacturing Innovation
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Stratasys Surges on Revenue Beat, Eyes Growth Amid Additive Manufacturing Innovation
Mar 7, 2024 10:06 AM

Stratasys, Ltd. ( SSYS ) shares are trading higher after the company reported fourth-quarter FY23 revenue of $156.3 million, beating the consensus of $154.2 million.

The adjusted gross margin expanded to 48.8% from 48.4% a year ago. Adjusted operating income was $2.0 million, down from $5.1 million a year ago.

Adjusted EBITDA fell to $7.7 million from $10.7 million the prior year. Adjusted EPS of $0.02 was in line with the consensus.

Cash used in operations stood at $(7.7) million, compared to $(18.1) million in fourth-quarter FY22. It held cash and equivalents of $162.6 million.

FY24 Outlook: The company expects revenue of $630 million-$645 million (consensus $644.09 million) and adjusted EPS of $0.12-$0.19 (consensus $0.26).

Stratasys ( SSYS ) sees an adjusted EBITDA outlook of $40 million-$45 million and adjusted operating margins of 2.5%-3.5%. The company also expects positive cash flow from operating activities.

Yoav Zeif, Chief Executive Officer, said, “We are innovating and investing as we expand our leadership in additive manufacturing. Our newest and most advanced FDM offering, the F3300, is building a strong pipeline of interest after announcing Toyota as its first customer, and engagement across our entire suite of offerings remains robust.” 

“As macro-economic conditions normalize and capital spending constraints ease, we believe the pent-up demand for our best-in-class offerings will unlock, driving the next phase of outsized growth and increased profitability for our company.”

In December 2023, the company disclosed receiving a preliminary acquisition proposal from Nano Dimension Ltd ( NNDM )  to buy all the remaining outstanding shares that it currently doesn’t own for $16.50 per share in cash.

Price Action: SSYS shares are trading higher by 7.16% at $12.43 on the last check Thursday.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Chinese developer Shimao sweetens debt revamp terms ahead of liquidation hearing, sources say
Chinese developer Shimao sweetens debt revamp terms ahead of liquidation hearing, sources say
Jun 25, 2024
HONG KONG (Reuters) - Shimao Group ( SIOPF ) has sweetened its offshore debt restructuring terms to garner support from creditors, said three sources, as the Chinese property developer scrambles to fend off a liquidation petition filed in a Hong Kong court. Shimao ( SIOPF ) will on Wednesday face its first court hearing into the liquidation petition filed by...
Chemours Resumes Production at Mexico Plant
Chemours Resumes Production at Mexico Plant
Jun 25, 2024
03:49 AM EDT, 06/25/2024 (MT Newswires) -- Chemours ( CC ) said late Monday it has resumed operations at its titanium dioxide factory in Altamira, Mexico, after the government lifted water intake restrictions that caused a temporary production pause. The company disclosed the temporary pause in production on May 31. Price: 23.71, Change: -0.22, Percent Change: -0.92 ...
Lotus Technology Strikes Deal for $110 Million Investment
Lotus Technology Strikes Deal for $110 Million Investment
Jun 25, 2024
03:56 AM EDT, 06/25/2024 (MT Newswires) -- Lotus Technology ( LOT ) said late Monday it reached a $110 million convertible bond agreement through a private placement from an existing shareholder. The company said the transaction is expected to close in the near future and will further strengthen its cash position. ...
Novo Nordisk's Wegovy weight-loss drug approved in China
Novo Nordisk's Wegovy weight-loss drug approved in China
Jun 25, 2024
SHANGHAI, June 25 (Reuters) - Novo Nordisk said on Tuesday its popular weight-loss drug Wegovy has been approved in China, paving the way for sales in the world's second-largest economy. Novo said in March that it would initially target Chinese patients willing to pay out-of-pocket for the weekly injectable drug. The company did not immediately respond to a Reuters request...
Copyright 2023-2025 - www.financetom.com All Rights Reserved